In August 2025 I was spoon-feeding my nineteen-year-old son at our kitchen table. He could not swallow, could not suck through a straw, voice volume dropped down to quiet. His face had become a mask — what the neurology textbooks call hypomimia, expressionless, mouth slightly open and unable to close. His arm did not know how to throw a ball any more. The Parkinsonism in his body was asymmetrical, which is a clinical red flag because drug-induced Parkinsonism is normally symmetrical and his was not. Sometimes he forgot to inhale. He vomited every day. He had been on Zuclopenthixol depot — a first-generation antipsychotic, at the maximum recommended dose — for fourteen months.

I am his well-educated mother. I am also tribunal-appointed Guardian and Financial Manager for my son, his Enduring Guardian and Attorney, and his designated carer. None of those qualifications mattered in the hospital corridor. What mattered, in those weeks, was that I had spent fourteen months reading the receptor papers and the metabolic-clearance papers and the supersensitivity papers while the rotating roster of more than twenty doctors across three regional hospitals continued to escalate, swap, and re-inject without ever reading the file as a whole. By the time my son could not swallow, I had asked, more than once, that the Zuclopenthixol be ceased. The treating team’s proposed alternative was Clozapine — the drug of last resort, with a mortality profile from “slow gut” alone that runs in the range of one in ten of those who develop the serious form.¹

High-risk profile

In October 2011 — fourteen years earlier — I had taken him for a hair mineral analysis. He was six years old. The analysis came back with five overlapping patterns: slow oxidation, the four-lows pattern, sympathetic dominance, mineral burnout, and poor elimination. In plainer English: his stress system was running far too hot for a child his age; his adrenals were already exhausted; his liver and kidneys had a documented difficulty clearing things out. I spent the next decade trying, with practitioners I trusted, to support what his body could not do on its own — to rebalance the minerals, to feed the elimination pathways, to give him the metabolic margin that the analysis said he did not have. He was, on paper and in person, a child who would not tolerate long-term dopamine-blocking drugs. That paper had been on my laptop’s desktop for fourteen years before any clinician was permitted to factor it into a prescribing decision.

Entry into the public healthcare or almost “cured to death”

He was exposed to severe family violence, and in later teen age got lost in the kinds of substances a body in pain reaches for.

In September 2023 he got admitted to a psychiatric ward for the first time with a drug-induced psychosis. In that admission I asked Dr Nicholas how can he be transferred to a rehabilitation centre, and was told there were no pathway until my son chose that himself. I asked how many times on average people get re-admitted before they go to a rehab or don’t have to be involuntarily admitted anymore. He responded “15 times”. It was a shocking statement. I could not believe the system is not wired to make it a one-time occurance.

We learnt the bad way.

One would expect that a mental health hospital would facilitate psychotherapy and daily psychologist sessions, mandatory daily drug-and-alcohol sermons.

NO. There is none. Zilch. Medical stuff is uninterested to address the underlying trauma. And 90 per cent of patients in psychiatric wards are young adults trapped in a substance abuse cycle.

The spiral that followed was my son would be discharged into the community and near immediately relapse into drug-use. He would be discharged on a psychotropic medication that kept him stripped off his willpower and motivation, a deadly tag-of-war between his desire to decide independently while being firmly hanging off the hook of involuntary medication injection.  

From September 2023 to August 2025 he was admitted to public psychiatric facilities fifteen times —  each time triggered by a more damaging illicit substance misuse. In nearly every one of those admissions I sat in family meetings and community-treatment Tribunal hearings, the same mother with the same metabolic history, the same lived knowledge of who this child had been at six and at sixteen and at eighteen.

By the time of the Zuclopenthixol depot the diagnosis on his file was “treatment-resistant schizophrenia.”

A label that psychiatry gives to the young substance-abuse patients, with unresolved PTSD, who they profoundly failed.

What every antipsychotic does to a brain

Every antipsychotic in the modern pharmacopoeia works by the same primary mechanism: it blocks the dopamine D2 receptor. The trouble is that dopamine does not flow through a single circuit. It flows through four.

• The first — the mesolimbic — is the one the drug is aimed at; blocking it dampens hallucinations and paranoia.

The other three are collateral damage.

• The mesocortical circuit governs cognition and working memory; blocking it makes thought slower, not sharper.
• The nigrostriatal circuit governs movement, and at a D2 occupancy above approximately 78 percent it produces the extrapyramidal syndrome the textbooks call EPS: dystonia, tremor, rigidity, facial masking, the inability to swallow.² First-generation drugs like Zuclopenthixol routinely run at 80–90 percent occupancy or higher.
• The fourth circuit, the tuberoinfundibular, governs prolactin; blocking it produces breast tissue growth, sexual dysfunction, and long-term bone loss.

Once the depot is injected, none of this can be undone. The drug is a slow-release reservoir in the muscle. If catastrophe arrives, the clinician cannot turn it off. The patient must wait — six to eight weeks of washout — while the neurological damage accumulates. In Āyurvedic language one would say the vāta doṣa has been radically and violently aggravated: the movement-principle has lost its rhythm, the limbs have stiffened, the breath has forgotten its own work, ojas — the deepest essence of vitality — has been spent. The modern receptor map and the ancient classification are not in competition. They are looking at the same animal from different windows. I had been looking at that animal, in this child, since he was under six.

The plants, and the molecules they brought to the table

So I did what mothers in unlivable rooms have always done: I went to the plants. Not as folklore or alternative medicine. As colleagues of the molecule — the elder colleagues, in fact, since most of the modern drug catalogue was first read out of leaves. I designed a protocol on three damage mechanisms simultaneously: the dopamine signalling shutdown in the basal ganglia, the oxidative stress and neuroinflammation that prolonged receptor blockade produces, and the disrupted acetylcholine–dopamine balance that drives rigidity and tremor.

For the GABA arm — the third great inhibitory neurotransmitter, the one that quiets a brain whose other circuits have been thrown out of balance — I layered five different botanicals, each binding the GABA-A receptor at a different site or by a different mechanism. Magnolia officinalis bark, at 600 milligrams a day, was the highest-dose component; its two neolignans magnolol and honokiol are positive allosteric modulators of the GABA-A receptor at the benzodiazepine site, with anxiolytic and muscle-relaxant activity comparable to a pharmaceutical benzodiazepine but without the dependency profile.³ Honokiol also crosses the blood–brain barrier readily and has been shown to protect dopaminergic neurons in the standard MPTP and 6-OHDA models of Parkinson’s disease — exactly the kind of neuroprotection the nigrostriatal circuit needed during the washout.

Passiflora incarnata — Passionflower — brought a triple-pathway GABAergic enhancement: direct GABA-A binding via chrysin and other flavonoids, inhibition of GABA transaminase to keep more GABA in the synapse, and inhibition of GABA reuptake. Its harman alkaloids carry a mild, reversible monoamine-oxidase inhibition that, in a brain pharmacologically depleted of dopamine, was meaningful. Ziziphus jujuba var. spinosa — Zizyphus — has been used in Traditional Chinese Medicine for persistent insomnia for two thousand years; its jujuboside A is a documented GABA-A modulator, its spinosin a 5-HT1A agonist. Eschscholzia californica, the California poppy, supplied non-opioid analgesia for dystonic muscles in pain. Piscidia piscipula, Jamaica dogwood, quieted the gut wall, where Zuclopenthixol had disrupted the heavily dopaminergic enteric nervous system — the so-called second brain. Lavandula angustifolia — lavender — closed the night circuit, with linalool reducing cortisol via the hypothalamic–pituitary–adrenal axis and dampening NMDA over-activation. Sleep, the deepest of the body’s repair shops, depends on quieting that axis. The protocol made that possible.

Then the targeted supplements ringed it: N-acetylcysteine as the rate-limiting precursor to glutathione — the brain’s own antioxidant defence, depleted by antipsychotic-induced oxidative stress, supported by randomised controlled trials in schizophrenia.⁴ Glutathione itself; MSM as a third entry into the sulphur pathway; calcium ascorbate; B12; B6 as the direct cofactor for dopamine synthesis; sodium bicarbonate to alkalinise the urine and accelerate the excretion of the basic depot compound — a documented principle from clinical toxicology, not a folk remedy.

And under all of this, the medhya rasāyana herbs of Āyurveda — the classical class of intellect-promoting rejuvenators, attested in the Caraka Saṃhitā more than two thousand years ago. Brāhmī (Bacopa monnieri), named for its association with Brahmā, whose bacosides rebalance acetylcholine and dopamine without the crude anticholinergic blockade of the standard psychiatric “side-effect drug” benztropine. Tulsī (Ocimum sanctum), Holy Basil, an adaptogen that normalises the HPA axis and provides eugenol and rosmarinic acid for inflammation. Ganoderma lucidum, Reishi, for nerve growth factor and microglial quietening. Scutellaria baicalensis, Baical skullcap, whose baicalein activates the Nrf2 pathway in dopaminergic neurons.⁵ Curcumin, chelating iron in the substantia nigra, where iron accumulation drives the slow oxidative murder of dopamine cells. Valerian, with valerenic acid showing affinity at the D2 receptor itself — pharmacologically analogous, at a milder scale, to the partial agonism of aripiprazole, the very drug the treating team’s own genetic testing had already identified as the right one for this patient.

The Turn — what the lab bench and the forest have in common

The receptors are real and the plants are real. The peer-reviewed citations beneath this article number more than twenty. What the manifesto demonstrates — quietly, in the language the institution claims to operate in — is that the body has always been a living ecology, and that the plants on the hillside are not a romantic alternative to the molecule but its original colleagues. The dopamine cell waiting to be rescued in the substantia nigra and the magnolia bark waiting on the apothecary shelf are two expressions of one biochemical conversation that long predates the pharmaceutical industry. To know prāṇa — the breath, the life-force — is to know that the body’s repair shops have always run on signals the forest also speaks: GABA, glutamate, glutathione, the cytochromes that the liver shares with every plant cell, the methyl groups that flow in and out of every living molecule. The discipline that listens to the body and the discipline that listens to the forest are the same discipline. The error of the revolving-door psychiatric system was not technical — it was the loss of that listening.

Thirty days

Within thirty days, while the depot depleted and the protocol held the line, my son crossed back. He swallowed. He spoke clearly. His shakes were gone to insignificant. The cognition returned. His subsequent relapses into substance use — the underlying condition the system had refused to name in fifteen admissions over two and a half years — do not invalidate the neurological recovery. They confirm what every addiction specialist knows: when you mask the symptom and ignore the cause, the symptom returns and the patient does not get better. Substance use disorder as the primary condition; psychosis as drug-induced; the so-called “treatment-resistant schizophrenia” largely iatrogenic dopamine supersensitivity from years of escalating D2 blockade.⁶ Beneath all of it, the complex post-traumatic stress disorder that began in childhood and has been documented but never treated. The manifesto names the differential diagnosis the system would not make.

What happened next is also in the document. In February 2026, the same system forced Clozapine on the same young man — a drug their own genetic testing said he was likely a non-responder to. In May 2026 they extended his involuntary detention by three months without informing his Guardian, took his phone away when he started attending Narcotics Anonymous meetings on the ward and calling private hospitals to self-admit, and prepared to transfer him to a facility eight hundred kilometres from his family. I am told, in writing, that they have applied for a Public Guardian to replace me. I have written back. I have served them with this manifesto. I am, in the author’s own words on the document’s front matter, offering it “as a clinical reference for private treating practitioners accepting my son’s care, and as a matter of public record.”

Why I am putting this on ecology.yoga

Because the body is the first ecology, and what is done to one nervous system in a hospital corridor in northern New South Wales in Australia is done, by extension, to the relationship every reader has with their own. Because the plants in this protocol — Brāhmī, Tulsī, Magnolia, Passiflora, Reishi — are the same plants the Āyurvedic and Chinese and Amazonian and Cherokee herbalists have known for centuries, and they are the same plants the receptor papers of the last three decades have been quietly confirming. Because I spoon-fed my son back to coherence using published pharmacology and the leaves on the hillside, and the system that hurt him called me unscientific until the day the receptors said otherwise. This is the bridge between yoga and ecology and culture that this platform exists to hold open: the body as a living forest, the practitioner as a listener at its edge, and the texts of every tradition that ever asked what the body actually is as the standing companions of whatever the peer-reviewed journal publishes next.

References

1. J. Boon (2026). Manifesto — Neuroprotective Detoxification Protocol for Drug-Induced Extrapyramidal Syndrome: Clinical Rationale and Documented Outcomes. A Parent’s Pharmacological Case Against the Revolving Door of Public Psychiatric Care. 16 May 2026, New South Wales. Full text embedded below.
2. Every-Palmer S, Ellis PM. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal ‘slow gut’ reactions, and comparison with international drug safety advice. CNS Drugs. 2017;31(8):699–709. doi:10.1007/s40263-017-0448-6
3. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry. 2000;157(4):514–520. doi:10.1176/appi.ajp.157.4.514
4. Alexeev M, Grosenbaugh DK, Mott DD, Fisher JL. The natural products magnolol and honokiol are positive allosteric modulators of both synaptic and extra-synaptic GABA(A) receptors. Neuropharmacology. 2012;62(8):2507–2514. doi:10.1016/j.neuropharm.2012.03.002
5. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia — a double-blind, randomized, placebo-controlled trial. Biological Psychiatry. 2008;64(5):361–368. doi:10.1016/j.biopsych.2008.03.004
6. Li Q, Li HH, Guo LX, et al. Baicalein protects against MPP+-induced oxidative stress by activating Nrf2/HO-1 signalling pathway in dopaminergic neurons. Oxidative Medicine and Cellular Longevity. 2020;2020:8139768. doi:10.1155/2020/8139768
7. Chouinard G, Samaha AN, Chouinard VA, et al. Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psychotherapy and Psychosomatics. 2017;86(4):189–219. doi:10.1159/000477313

The Manifesto — Full Text

Skip to PDF content